{"id":579252,"date":"2021-12-15T20:12:01","date_gmt":"2021-12-15T20:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=579252"},"modified":"2021-12-15T20:12:01","modified_gmt":"2021-12-15T20:12:01","slug":"asthma-therapies-key-companies-and-pipeline-landscape-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/asthma-therapies-key-companies-and-pipeline-landscape-analysis-by-delveinsight_579252.html","title":{"rendered":"Asthma Therapies, Key Companies and Pipeline Landscape Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1639550367.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Asthma Therapies, Key Companies and Pipeline Landscape Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1639550367.png\" alt=\"Asthma Therapies, Key Companies and Pipeline Landscape Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Asthma Pipeline<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">There are currently 100+ companies working in the Asthma pipeline landscape.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/asthma-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Asthma pipeline report<\/a><\/strong> provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Asthma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>There are currently <strong>100+ drugs<\/strong> in the Asthma pipeline.<\/li>\n<li>The Asthma pipeline consists of therapies in different clinical phase stages, including <strong>Depemokimab, FB704A, MEDI 3506, AQ001S, MRx-4DP0004, SHR-1703,<\/strong> and others.<\/li>\n<li>Leading companies actively working to improve the Asthma treatment landscape are <strong>GlaxoSmithKline, Oneness Biotech, AstraZeneca, Aquilon Pharma, 4D Pharma PLC, Jiangsu Hengrui Medicine,<\/strong> and others.<\/li>\n<li>Key Asthma pipeline therapies in the late stage of development include <strong>Depemokimab (GlaxoSmithKline), FB704A (Oneness Biotech), MEDI 3506 (AstraZeneca),<\/strong> and others.<\/li>\n<li><strong>SHR-1703<\/strong> is being developed and evaluated in the phase 1 Asthma clinical trials by <strong>Jiangsu Hengrui Medicine.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Get a detailed analysis of the pipeline landscape @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/asthma-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Asthma Pipeline Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Asthma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Asthma is a chronic disease that affects the airways, also known as the bronchial tubes. It is a diverse disease with episodes of airway narrowing or hyperresponsiveness, obstruction, inflammation, and mucous production. The narrowing of the airways causes shortness of breath and coughing. Different inflammatory pathways are responsible for the airway inflammation and hyperresponsiveness associated with asthma.<\/p>\n<p style=\"text-align: justify;\"><strong>Asthma Symptoms<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\">Asthma symptoms can vary from person to person. However, the most common asthma symptoms are shortness of breath, wheezing, coughing, and chest tightness. Over time, these symptoms can progress from mild to severe. Asthma symptoms can worsen and cause asthma attacks in some people.<\/p>\n<p style=\"text-align: justify;\"><strong>Asthma Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\">Asthma currently has no cure or specific treatment, but medication and lifestyle changes can help relieve symptoms. Long-term control treatments for asthma, such as inhaled corticosteroids, long-acting beta-agonists, and oral medications, are currently available. Oral corticosteroids, beta-agonists, and inhaled bronchodilators are used to treat acute episodes.<\/p>\n<p style=\"text-align: justify;\"><strong>Asthma Pipeline Analysis: Drug Profiles<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Depemokimab: GlaxoSmithKline<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Product Description<\/strong><\/p>\n<p style=\"text-align: justify;\">Depemokimab, an Interleukin 5 receptor antagonist monoclonal antibody currently in development by GlaxoSmithKline, is being developed to treat severe asthma with an eosinophilic phenotype.<\/p>\n<p style=\"text-align: justify;\"><strong>Phase III<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>NCT04719832:<\/strong> GlaxoSmithKline initiated a Phase III, 52-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of gsk3511294 adjunctive therapy in adults and adolescents with severe uncontrolled asthma with an eosinophilic phenotype in March 2021. gsk3511294 (depemokimab) is being developed as a long-acting (la) injectable anti-interleukin-5 (anti-il-5) therapy with an efficacy and safety profile comparable to current anti-il-5 therapies but with a lower dosing frequency.<\/p>\n<p style=\"text-align: justify;\"><strong>Asthma Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Depemokimab: GlaxoSmithKline<\/li>\n<li>FB704A: , and asthmaOneness Biotech<\/li>\n<li>MEDI 3506: AstraZeneca<\/li>\n<li>AQ001S: Aquilon Pharma<\/li>\n<li>MRx-4DP0004: 4D Pharma PLC<\/li>\n<li>SHR-1703: Jiangsu Hengrui Medicine<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out the emerging therapies and companies @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/asthma-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Asthma Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Asthma Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By Product Type<\/strong><\/li>\n<ul>\n<li>Monotherapy<\/li>\n<li>Combination Therapy<\/li>\n<\/ul>\n<li><strong>By Stage<\/strong><\/li>\n<ul>\n<li>Discovery<\/li>\n<li>Pre-Clinical<\/li>\n<li>Phase I<\/li>\n<li>Phase II<\/li>\n<li>Phase III<\/li>\n<li>Pre-registration<\/li>\n<\/ul>\n<li><strong>By Route of Administration<\/strong><\/li>\n<ul>\n<li>Inhalation<\/li>\n<li>Intravenous<\/li>\n<li>Oral<\/li>\n<li>Subcutaneous<\/li>\n<\/ul>\n<li><strong>By Molecule Type<\/strong><\/li>\n<ul>\n<li>Small Molecule<\/li>\n<li>Stem Cell Therapy<\/li>\n<li>Gene Therapy<\/li>\n<\/ul>\n<li><strong>Targets<\/strong><\/li>\n<ul>\n<li>Immune System<\/li>\n<li>Multiple Kinase<\/li>\n<\/ul>\n<li><strong>By Mechanism of Action<\/strong><\/li>\n<ul>\n<li>Protease Inhibitors<\/li>\n<li>Immunomodulatory<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Coverage:<\/strong> Global<\/p>\n<p style=\"text-align: justify;\"><strong>Asthma Key Players:<\/strong> GlaxoSmithKline, Oneness Biotech, AstraZeneca, Aquilon Pharma, 4D Pharma PLC, Jiangsu Hengrui Medicine, among others<\/p>\n<p style=\"text-align: justify;\"><strong>Asthma Pipeline Therapies:<\/strong> Depemokimab, FB704A, MEDI 3506, AQ001S, MRx-4DP0004, SHR-1703, and others<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong>&nbsp;<\/p>\n<table border=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1.<\/p>\n<\/td>\n<td>\n<p>Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2.<\/p>\n<\/td>\n<td>\n<p>Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3.<\/p>\n<\/td>\n<td>\n<p>Asthma: Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4.<\/p>\n<\/td>\n<td>\n<p>Asthma Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5.<\/p>\n<\/td>\n<td>\n<p>Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.<\/p>\n<\/td>\n<td>\n<p>Late Stage Products (Registered)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.<\/p>\n<\/td>\n<td>\n<p>Late Stage Products (Phase&nbsp; III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8.<\/p>\n<\/td>\n<td>\n<p>Mid Stage Products (Phase&nbsp; II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9.<\/p>\n<\/td>\n<td>\n<p>Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10.<\/p>\n<\/td>\n<td>\n<p>Early-stage Products (Phase 1)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11.<\/p>\n<\/td>\n<td>\n<p>Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12.<\/p>\n<\/td>\n<td>\n<p>Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13.<\/p>\n<\/td>\n<td>\n<p>Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14.<\/p>\n<\/td>\n<td>\n<p>Asthma Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15.<\/p>\n<\/td>\n<td>\n<p>Asthma Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16.<\/p>\n<\/td>\n<td>\n<p>Asthma Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17.<\/p>\n<\/td>\n<td>\n<p>Asthma Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18.<\/p>\n<\/td>\n<td>\n<p>Asthma Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19.<\/p>\n<\/td>\n<td>\n<p>Asthma Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20.<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>21.<\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">Get in touch with our business executive for <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Healthcare Due Diligence Services<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key questions answered in the Asthma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are Asthma treatments available?<\/li>\n<li>How are many pharmaceutical companies developing asthma treatments?<\/li>\n<li>Which of these companies&#8217; pharmaceuticals is the most commonly used?<\/li>\n<li>How many Asthma medications are manufactured by each company?<\/li>\n<li>How many asthma drugs are in the early, mid, or late stages of development?<\/li>\n<li>How many of the currently being developed therapies can be used alone or in combination with other treatments?<\/li>\n<li>What are the critical Asthma collaborations, mergers and acquisitions, and licensing practices?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/asthma-diagnostic-devices-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Asthma Diagnostic Devices Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">Get a comprehensive analysis of Asthma Diagnostic Devices pipeline devices and key companies, including <strong>Medline Industries, Inc., Becton, Dickinson and Company, Siemens Process Instrumentation, Smiths Medical, Vyaire Medical, Inc., Nihon Kohden Corporation, Vitalograph, Circassia Limited,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=asthma-therapies-key-companies-and-pipeline-landscape-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=asthma-therapies-key-companies-and-pipeline-landscape-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Asthma Pipeline There are currently 100+ companies working in the Asthma pipeline landscape. DelveInsight&rsquo;s Asthma pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/asthma-therapies-key-companies-and-pipeline-landscape-analysis-by-delveinsight_579252.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-579252","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/579252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=579252"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/579252\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=579252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=579252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=579252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}